Firstsource Solutions





Stellar performance driving up Guidance and Profitability

- Firstsource (FSL) reported above expectation results, with a sequential revenue growth of 13% at \$160mn (DE: 8%) led by sustained traction in BFSI Vertical (up 15% QoQ in \$ terms) and very sharp recovery in CMT segment (clocked 31% QoQ growth). Strong offshore led growth led to OPM improvement of about 40bps QoQ at 11.4% (DART estm: 11.1%).
- Robust growth performance and healthy client wins (added 15 client wins in Q2, 10 in Q1) led to upgrade in revenue guidance for FY21 to 9-12% (from 6% to 10% growth in CC terms). OPM outlook kept intact at 11.0% to 11.5%, as company expect further need for investments in new vertical/capabilities and increased cost on talent (in mortgage).
- Commentary remain confident given favorable macros in the Mortgage segment (New housing sales at multi-year high & interest rates at record lows), increased delinquency (good for Collections unit) and lower claims for Payers. CMT business recovered sharply as Top-client revived volumes beyond emergency services. The only concern now is within Provider segment (~15% of rev) that may remain subdue as elective surgeries continues to remain weak.
- Strong upgrade in guidance (growth leader across IT&ITeS names in FY21), robust client additions, improved profitability, widened bandwidth & market opportunities, reducing client concentration, generous payouts (imply 5% yield) and compelling valuations (~10x on TMF basis) makes a strong case for re-rating of the stock. Thus, we maintain our Buy rating with TP of Rs100 (valued at 12x on FY23E).

Guidance implies top-of-the-charts growth

FSL growth guidance even at mid-point (10.5%) would imply that it may lead peers and above on growth front in FY21E. More importantly growth is quite broad based (unlike in past) and is likely to sustain in near future given sound underlying macros and its well complementing offerings (has enhanced all its Platform offerings to support Digital transformation opportunities). Well-enhanced bandwidth across existing as well as new initiatives are bearing the desired results as evident from strong deal wins (added 25 clients in H1 alone) and expanding pipeline. This is a significant shift from its performance over the years and thus, with its growth performance now taking a big leap, we see a significant room for re-rating potential in the stock.

Q2FY21 Result (Rs Mn)

Particulars	Q2FY21	Q2FY20	YoY (%)	Q1FY21	QoQ (%)
Revenue	11,877	9,849	20.6	10,622	11.8
Total Expense	10,001	8,525	17.3	8,954	11.7
EBITDA	1,876	1,325	41.7	1,668	12.5
Depreciation	519	455	14.0	498	4.0
EBIT	1,358	870	56.1	1,170	16.1
Other Income	21	65	(68.1)	(1)	(1768.8)
Interest	124	129	(3.6)	134	(6.9)
EBT	1,254	806	55.6	1,035	21.2
Tax	202	132	52.2	148	36.1
RPAT	1,053	674	56.2	887	18.7
APAT	1,053	674	56.2	887	18.7
			(bps)		(bps)
Gross Margin (%)	32.8	31.8	102	32.9	(12)
EBITDA Margin (%)	15.8	13.4	235	15.7	9
NPM (%)	8.9	6.8	202	8.3	52
Tax Rate (%)	16.1	16.4	(36)	14.3	176
EBIT Margin (%)	11.4	8.8	260	11.0	42

CMP			Rs 71				
Target / Upside		Rs 100	/ 41%				
NIFTY	11,671						
Scrip Details							
Equity / FV	Rs 6,93	38mn /	Rs 10				
Market Cap	Rs 49br						
	USD 664mr						
52-week High/Low		Rs 7	78/ 20				
Avg. Volume (no)		41,7	6,780				
Bloom Code		FS	OL IN				
Price Performance	1M	3M	12M				
Absolute (%)	(1)	52	41				
Rel to NIFTY (%)	(1)	51	44				

Shareholding Pattern

	Mar'20	Jun'20	Sep'20
Promoters	53.9	53.9	53.8
MF/Banks/Fls	12.4	12.7	14.0
FIIs	9.5	8.1	7.0
Public / Others	24.2	25.4	25.2

Valuation (x)

	FY21E	FY22E	FY23E
P/E	11.7	9.8	8.6
EV/EBITDA	7.2	6.0	5.2
ROE (%)	14.8	16.5	17.8
RoACE (%)	13.7	15.7	17.3

Estimates (Rs mn)

	FY21E	FY22E	FY23E
Revenue	47,685	55,121	60,987
EBITDA	7,543	8,723	9,702
PAT	4,225	5,030	5,728
EPS (Rs.)	6.1	7.2	8.2

VP - Research: Rahul Jain Tel: +9122 40969771 E-mail: rahulj@dolatcapital.com

Associate: Divyesh Mehta Tel: +91 22 40969768

E-mail: divyesh.mehta@dolatcapital.com



Exhibit 1: Quarterly performance versus estimates

		Estimates		% Va	riation	
(Rs mn)	Actual	Dolat	Consensus	Dolat	Consensus	Comment
Revenue (\$ mn)	160	152	NA	4.9	NA	Revenue bear was led by surprise
INR Revenue	11,877	11,394	NA	4.2		30% recovery in CMT, along with 13% growth in BFSI vertical.
EBIT	1,358	1,265	NA	7.4	. NA	OPM beat was led by better growth that too led by higher offshore
EBIT, margin	11.4	11.1	NA	30.0	NA NA	delivery mix
PAT	1,053	973	NA	8.3	NA	PAT beat was further extended by lower net interest charge.

Source: Company, DART

Change in Estimates

Post the stellar performance in Q2, upgraded guidance (200bps on top-end of band) and confident commentary across business units (85% of business would show sustained traction) we have upgraded our growth outlook for the company overall by 2%/3.3% in FY21/22E. However, given the reinvestment approach we have kept our margin estimate largely intact (well within guided band of 11%-11.5%). We have also introduced our estimates for FY23 baking in revenue growth of 9.2% YoY and OPM at 11.4%.

The growth assumptions factors in sustained traction in BFSI, improved volumes in CMT and gradual recovery in Provider segment within Healthcare vertical. We believe our growth/margin are bit conservative compared to outlook shared by the company and thus have some upside risk to our estimates.

Exhibit 2: Change in Estimates

	FY20A		FY21E			FY22E		FY23E
(in Rs mn, except EPS)	Actual	Old	New	change	Old	New	change	New
Revenues (\$ mn)	578	629	641	2.0	706	730	3.3	797
YoY growth (%)	5.7	8.8	11.0	216.3	12.3	13.8	148.5	9.2
INR Revenue	40,986	47,125	47,685	1.2	53,353	55,121	3.3	60,987
YoY growth (%)	7.1	15.0	16.3	136.5	13.2	15.6	237.8	10.6
EBIT	4,437	5,241	5,405	3.1	6,016	6,242	3.8	6,958
EBIT margin (%)	10.8	11.1	11.3	21.4	11.3	11.3	4.9	11.4
PAT	3,397	4,032	4,225	4.8	4,800	5,030	4.8	5,728
EPS (Rs)	4.9	5.8	6.1	4.7	6.9	7.2	4.7	8.2

Source: DART, Company

Exhibit 3: Key Revenue Assumptions

Key Assumptions	FY20A	FY21E	FY22E	FY23E								
USD revenue growth (%)	5.7	11.0	13.8	9.2								
INR revenue growth (%)	7.1	16.3	15.6	10.6								
EBIT margin (%)	10.8	11.3	11.3	11.4								
EPS growth (%)	(10.4)	24.2	19.1	13.9								
USD/INR	70.1	73.8	75.0	76.0								



Exhibit 4: Quarterly and YTD Financial Performance Trends

Rs mn	Q1FY20	Q2FY20	Q3FY20	Q4FY20	Q1FY21	Q2FY21	QoQ	YoY	YTDFY2 0	YTDFY2 1	YoY
Revenues(\$ mn)	141	140	148	149	141	160	13.3	14.1	281	301	7.0
Revenue	9,798	9,849	10,535	10,804	10,622	11,877	11.8	20.6	19,647	22,499	14.5
Operating Expense	8,141	8,525	8,868	9,163	8,954	10,001	11.7	17.3	16,666	18,955	13.7
Employee Expenses	6,611	6,722	7,053	7,350	7,128	7,985	12.0	18.8	13,333	15,113	13.4
as % of sales	67.5	68.2	66.9	68.0	67.1	67.2			67.9	67.2	
Other Expense	1,530	1,803	1,816	1,813	1,826	2,016	10.4	11.8	3,333	3,841	15.3
as % of sales	15.6	18.3	17.2	16.8	17.2	17.0			17.0	17.1	
EBITDA	1,657	1,325	1,666	1,641	1,668	1,876	12.5	41.7	2,981	3,544	18.9
Depreciation	439	455	484	474	498	519	4.0	14.0	894	1,017	13.8
EBIT	1,217	870	1,182	1,168	1,170	1,358	16.1	56.1	2,087	2,527	21.1
Net interest	(115)	(129)	(159)	(142)	(134)	(124)	(6.9)	(3.6)	(244)	(258)	5.8
Other Income	(34)	65	12	6	(1)	21			32	20	(38)
PBT	1,069	806	1,036	1,031	1,035	1,254	21.2	55.6	1,875	2,289	22.1
Total Tax	157	132	140	115	148	202	36.1	52.2	290	350	20.7
Minorities	(0)	(0)	0	0	0	(0)			(0)	(0)	
Reported PAT	912	674	895	916	887	1,053	18.7	56.2	1,586	1,940	22.3
Reported EPS	1.3	1.0	1.3	1.3	1.3	1.5	18.6	56.0	2.3	2.8	22.2
Margins (%)							(bps)	(bps)			(bps)
EBITDA	16.9	13.4	15.8	15.2	15.7	15.8	51	(121)	15.2	15.8	(58)
EBIT	12.4	8.8	11.2	10.8	11.0	11.4	21	(141)	10.6	11.2	(61)
PBT	10.9	8.2	9.8	9.5	9.7	10.6	20	(117)	9.5	10.2	(63)
PAT	9.3	6.8	8.5	8.5	8.3	8.9	(13)	(96)	8.1	8.6	(55)
Eff. Tax rate	14.7	16.4	13.6	11.2	14.3	16.1	313	(40)	15.4	15.3	18

Source: DART, Company

What to expect next Quarter

We expect sustained growth traction with 4% growth QoQ in CC terms in revenues for Q3 led by sustained demand backlog in BFSI/Payer segment. We expect OPM to remain flat QoQ as the company remain committed to investments in people, capability and also on increased supply side constraints in mortgage segment.

Exhibit 5: What to expect next Quarter

Extribit 51 11 list to expect liest quality.											
(Rs Mn)	Q3FY21E	Q2FY20	Q3FY20	QoQ (%)	YoY (%)						
Sales (\$ mn)	166	160	148	4.0	12.3						
Sales	12,285	11,877	10,535	3.4	16.6						
EBIT	1,401	1,358	1,182	3.1	18.5						
PAT	1,107	1,053	895	5.1	23.6						
EPS (Rs)	1.6	1.5	1.3	5.1	23.4						
EBIT Margin (%)	11.4	11.4	11.2	-3 bps	18 bps						

Source: Company, DART



Key Highlights from Earning Call

- Revenue: Revenue stood at \$158.3mn grew 12.2% QoQ and 13.1% YoY in constant currency in CC terms led by robust uptick in BFSI (New housing sales as well as Refinance volumes) and CMT segment (client has revived volumes). The Healthcare segment witnessed stability as lower elected surgeries in Provider sub-segment has been negating the robust volume traction in Payer segment.
- **EBIT Margin** stood at 11.4% improved 42bps on QoQ basis led by strong growth traction (improved utilization) and offshore shift gains (up 220bps at 27%, offshore revenues up 23%). Profitability guidance however, has been kept unchanged at 11-11.5% as expects need for investment and increased talent cost (witnessing some supply side issue in mortgage industry).
- Vertical wise commentary: Diverse Industries (2.2% of Rev) degrew 7.7%
 QoQ.
- BFSI (51.9% of Rev) grew 14.9% QoQ led by sustained demand in both refinance mortgage and purchase mortgage segment as New Housing sales are up over 21% on YoY basis. The demand on Refinancing side also continues to do well as interest rates are at record low and has resulted in over 60% home-loans now being in-the-money and thus should remain the driving factor supporting growth for several quarters more. Between origination and Servicing mix is 2/3 and 1/3 respectively and thus provides comfort on longevity. On Collection side the volumes are going up given increased unemployment driving up the delinquencies (up 400bps on QoQ basis). The trends for loans business is mix as Covid has impacted different segments differently.
- Healthcare (27.1% of Rev) grew 2.7% QoQ due to traction in new-trends such as Telehealth, remote patient monitoring and medical devices but the growth remain muted on account of lower elective procedures, lower patient volumes (low for last six month from avg 2019 levels), and increase in time to convert medical payments to revenues due to slower billing from hospitals (resource constraints). However, the company is hopeful as it has been building healthy pipeline in remote customer engagement, online data portals processing and payments. Also, the Payer segment is witnessing huge traction given lower claims. The Payer and Provider mix stand at 43% and 57% respectively. The payer segment saw demand as health plans are witnessing fewer claims while Provider segment may see improvement as proportion of Self-pay may go up given rising unemployment.
- CMT (18.8% of Rev) grew 31.5% QoQ led by improved volume growth in Top client as it has normalized Contact-center-support beyond emergency services and as it was able to move some of its offerings on WFH mode in the quarter. The company expects to reach pre Covid levels volumes by Q3 or Q4 (this can add 1.5% to overall revenue growth).
- Geography Commentary: US (68.1% of Rev) grew 11.7% QoQ. UK (30.6% of Rev) grew 16.8% QoQ and company expects traction in UK financial service sector in coming quarters as UK financial institution want to increase digital access to customer with lower and sustainable cost base. RoW (1.3% of Rev) grew 22.8% QoQ.
- Service lines Commentary: Digitally Empowered Contact Centre (49.1% of Rev) grew 15.9% QoQ. Intelligent Back Office (42.9% of Rev) grew 11.2% QoQ. Platforms, Automation & Analytics (8% of Rev) grew 9.2% QoQ and witnessed a strong pipeline on account of demand from clients for transformative and digital conversations.



- Client: Company won 15 deals of which 11 belongs to BFS (wherein Mortgage has a major share in it) and 4 in Healthcare vertical (LQ added 10 new deals). Most of the deals had a quick start volumes and has contributed to revenue growth in Q2 as well. Client concentration has been coming off with Top customer now accounting 16% of revenues. Top 5 clients consist healthy mix of clients from CMT, Healthcare and BFSI.
- Onshore/Offshore mix: Clients demand for offshore delivery (observed 220bps shift in Q2) has been increasing since last quarter and in servicing for mortgage sub segment few components of it will move from onshore to offshore. However, do not see offshore as any significant growth driver.
- Strategy: strategy is built on three key fundamentals viz: 1) Focus on Core process that is all the key vertical segments by building right relationships and right services to create differentiated position and momentum in the market. 2) Modernization of offerings by digitally empowering tech centers or back offices platform through automation and analytics and 3) Continuous investment in operating capacity, right leadership and account management capacity to build scalable organization as well as sustainable growth in business.

Band Chart


Exhibit 6: Valuation compelling at under 12x one TMF basis. The stock is all set to re-rate






Story in Charts

Exhibit 7: Revenue traction improve furthermore...




Source: DART, Company

Exhibit 8: Led by sustained traction in BFSI,




Source: DART, Company

Exhibit 9: ..that covered up for softness in HealthCare




Source: DART, Company

Exhibit 10: Recovery in CMT segment has aided in



Source: DART, Company

Exhibit 11: Further gains in OPM by 40bps



Source: DART, Company

Exhibit 12: New Client Wins Trend remain healthy






Exhibit 13: Operating Metrics 1

Operating Metrics	Q1FY19	Q2FY19	Q3FY19	Q4FY19	Q1FY20	Q2FY20	Q3FY20	Q4FY20	Q1FY21	Q2FY21
\$ Revenue	137	7 136	137	137	141	140	148	3 149	141	L 160
CC growth (%) (YoY)	(0.1) 3.2	3.5	3.8	5.2	4.5	8.3	8.2	1.6	5 13.1
CC growth (%) (QoQ)	1.1	L 1.8	0.9	0.7	2.0	1.1	4.7	7 0.6	(4.3) 12.2
Geographical Se	egment An	nount								
US& Canada	75	5 76	77	76	81	. 87	' 94	95	98	3 110
UK	62	2 60	61	. 60	59	52	. 53	3 53	42	<u>2</u> 49
Rest of world	2	2 2	. 1	. 2	. 2	. 2	. 2	2 2	. 2	2 2
Geographical Se	egment Yo	Y Growth								
US& Canada	5.0	6.9	3.3	(2.0)	8.3	15.4	23.3	3 25.4	20.6	5 25.5
UK	10.8	3 (1.8)	(1.6)	(0.6)	(4.3)	(13.0)	(13.3)	(11.1)	(29.0) (5.9)
Rest of world	(80.2) (57.1)	1.1	. (9.7)	19.9	40.7	50.5	49.7	' (14.7) (1.7)
Vertical Segme	nt Amount									
BFSI	48	3 49	48	50	51	. 57	64	65	73	84
Telecom & Media	40) 38	40	38	39	31	. 33	3 35	5 23	3 30
Healthcare	49	9 48	47	' 46	48	49	48	3 47	' 42	2 44
Others	2	2 3	4	. 4	. 5	4	. 4	5	, 2	1 4
Vertical Segme	nt YoY Gro	wth								
BFSI	30.8	3 23.8	19.4	13.3	5.5	16.8	33.3	30.1	. 43.1	L 45.8
Telecom & Media	(20.5) (19.4)	(13.5)	(12.6)	(1.9)	(17.7)	(17.4)) (8.6)	(40.8) (3.0)
Healthcare	(0.4) (2.1)	(7.8)	(13.0)	(2.4)	2.3	2.2	2 3.5	(11.2) (10.9)
Others	665.9	9 1,824.5	0.0	0.0	153.6	68.4	7.5	5 2.9	(27.4) (19.5)
Business Segme	ent Amoun	t								
Digitally Empow	ered Cont	act Center			79	74	. 74	1 77	' 68	3 79
Intelligent Back	Office				57	60	67	7 64	62	2 69
Platforms, Auto	mation & A	Analytics			7	8	8	3 10	12	2 13
Business Segme	ent YoY Gro	owth								
Digitally Empow	ered Cont	act Center							(13.5	7.6
Intelligent Back	Office								9.8	3 14.3
Platforms, Auto	mation & A	Analytics							58.8	62.1
Delivery Type A	mount									
Off-Shore	32	2 27	25	25	32	. 32	. 38	39	35	5 43
On-Shore	107	7 110	114	112	111	110	112	2 112	107	7 118
Delivery Type Y	oY Growth									
Off-Shore	14.0	(5.4)	(16.5)	(16.0)	0.1	18.3	49.7	7 51.9	9.6	34.4
On-Shore	7.4	1 6.6	7.4	4.2	3.6	(0.5)	(1.8)	0.2	(3.5	7.3
Top Client Amo	unt									
Top client	34	1 33	35	34	. 36	28	29	31	. 19	9 26
Top 2-5 client	25	5 24	. 23	24	. 23	28	34	1 33	37	7 39
Top 5 client	59	57	57	58	59	56	63	8 64	57	7 65
Non-Top 5 clients	80) 80	82	. 79	84	. 86	86	5 87	85	96
Top Client YoY	Growth				-					
Top client	(9.3) (17.2)	(13.8)	(10.2)	3.6	(14.1)	(15.8)) (9.4)	(45.3) (7.2)
Top 2-5 client	(3.8) (0.9)	(10.0)	(3.6)	(6.9)	14.2	49.1	35.8	59.9	····
Top 5 client	(7.0) (10.9)	(12.3)	(7.6)	(0.8)	(2.0)	9.9	9.5	(3.7) 16.1
Non-Top 5 clients	10.2	2 12.2			5.5			10.0		



Exhibit 14: Operating Metrics 2

Employee Data	Q1FY19	Q2FY19	Q3FY19	Q4FY19	Q1FY20	Q2FY20	Q3FY20	Q4FY20	Q1FY21	Q2FY21
Total Employees	18,759	19,615	18,595	18,712	18,550	20,001	20,482	21,203	21,831	23,960
Breakup										
India	8,664	9,040	8,621	8,968	9,305	10,493	10,982	11,450	11,684	13,536
Outside India	10,095	10,575	9,974	9,744	9,245	9,508	9,500	9,753	10,147	10,424
Seats	16,287	16,617	16,449	15,964	15,956	16,594	17,261	17,559	17,537	17,500
Seat fill factor	74.0	71.0	78.0	82.0	74.0	75.0	87.0	79.0	NA	NA
Attrition										
Offshore(India and Philliphines)	51.7	44.8	39.3	41.5	45.3	40.0	36.0	33.5	15.1	26.3
Onshore (US and Europe)	48.7	54.9	45.8	42.9	46.8	54.6	45.8	41.9	30.2	47.3



(Rs Mn)	FY20A	FY21E	FY22E	FY23E
Revenue	40,986	47,685	55,121	60,987
Total Expense	34,697	40,142	46,398	51,285
COGS	27,735	32,057	37,041	40,933
Employees Cost	0	0	0	0
Other expenses	6,962	8,085	9,357	10,352
EBIDTA	6,289	7,543	8,723	9,702
Depreciation	1,852	2,138	2,480	2,744
EBIT	4,437	5,405	6,242	6,958
Interest	545	491	433	408
Other Income	50	58	145	270
Exc. / E.O. items	0	0	0	0
EBT	3,942	4,972	5,954	6,820
Tax	545	747	923	1,091
RPAT	3,397	4,225	5,030	5,728
Minority Interest	0	0	0	0
Profit/Loss share of associates	0	0	0	0
APAT	3,397	4,225	5,030	5,728
	•	•	<u> </u>	
Balance Sheet				
(Rs Mn)	FY20A	FY21E	FY22E	FY23E
Sources of Funds				
Equity Capital	6,938	6,938	6,938	6,938
Minority Interest	6	6	6	6
Reserves & Surplus	20,716	22,509	24,413	25,972
Net Worth	27,654	29,447	31,351	32,911
Total Debt	8,369	6,869	5,669	4,669
Net Deferred Tax Liability	(1,776)	(1,776)	(1,785)	(1,785)
Total Capital Employed	34,253	34,546	35,241	35,800
Applications of Funds				
Net Block	28,709	28,121	26,990	25,746
CWIP	0	0	0	0
Investments	122	122	122	122
Current Assets, Loans & Advances	14,528	15,712	18,150	20,269
Inventories	0	0	0	0
Receivables	5,567	6,271	7,098	7,686
Cash and Bank Balances	1,907	2,037	2,877	3,925
Loans and Advances	0	0	0	0,5_5
Other Current Assets	7,054	7,405	8,176	8,658
	- ,	.,	-,	-,
		9,409	10,022	10,336
Less: Current Liabilities & Provisions	9,107	J, - UJ	10,022	
	9,107 953			
Less: Current Liabilities & Provisions Payables Other Current Liabilities	953	1,100	1,271	1,265
Payables				1,265 9,072
Payables Other Current Liabilities	953	1,100	1,271	1,265

E – Estimates



Important Ratios Particulars	FY20A	FY21E	FY22E	FY23E
(A) Margins (%)				
Gross Profit Margin	32.3	32.8	32.8	32.9
EBIDTA Margin	15.3	15.8	15.8	15.9
EBIT Margin	10.8	11.3	11.3	11.4
Tax rate	13.8	15.0	15.5	16.0
Net Profit Margin	8.3	8.9	9.1	9.4
(B) As Percentage of Net Sales (%)				
COGS	67.7	67.2	67.2	67.1
Employee	0.0	0.0	0.0	0.0
Other	17.0	17.0	17.0	17.0
(C) Measure of Financial Status				
Gross Debt / Equity	0.3	0.2	0.2	0.1
Interest Coverage	8.1	11.0	14.4	17.1
Inventory days	0	0	0	
Debtors days	50	48	47	46
Average Cost of Debt	7.9	6.4	6.9	7.9
Payable days	8	8	8	
Working Capital days	48	48	54	59
FA T/O	1.4	1.7	2.0	2.4
(D) Measures of Investment				
AEPS (Rs)	4.9	6.1	7.2	8.2
CEPS (Rs)	7.6	9.2	10.8	12.2
DPS (Rs)	3.0	3.5	4.5	4.5
Dividend Payout (%)	61.5	57.6	62.2	54.6
BVPS (Rs)	39.9	42.4	45.1	47.4
RoANW (%)	12.4	14.8	16.5	17.8
RoACE (%)	12.1	13.7	15.7	17.3
RoAIC (%)	14.2	16.7	19.2	21.7
(E) Valuation Ratios	11.2	10.7	13.2	21.7
CMP (Rs)	71	71	71	71
P/E	14.5	11.7	9.8	8.6
Mcap (Rs Mn)	49,402	49,402	49,402	49,402
MCap/ Sales	1.2	1.0	0.9	0.8
EV	55,863	54,234	52,194	50,146
EV/Sales	1.4	1.1	0.9	0.8
EV/EBITDA	8.9	7.2	6.0	5.2
P/BV	1.8	1.7	1.6	1.5
Dividend Yield (%)	4.2	4.9	6.3	6.3
(F) Growth Rate (%)	112	1.3	0.0	0.0
Revenue	7.1	16.3	15.6	10.6
EBITDA	17.5	19.9	15.6	11.2
EBIT	(3.8)	21.8	15.5	11.5
PBT	(9.6)	26.1	19.7	14.5
APAT	(10.1)	24.4	19.1	13.9
EPS	(10.4)	24.2	19.1	13.9
	(10.4)	24.2	13.1	10.0
Cash Flow	EV20.4	51045	EVOOF	51/005
(Rs Mn)	FY20A	FY21E	FY22E	FY23E
CFO	4,104	6,102	6,950	8,125
CFI	143	(2,041)	(1,783)	(1,908
CFF	(2,768)	(3,932)	(4,327)	(5,169
FCFF	2,972	4,552	5,600	6,625
Opening Cash	474	1,907	2,037	2,877
Closing Cash	1,907	2,037	2,877	3,925



DART RATING MATRIX

Total Return Expectation (12 Months)

Buy	> 20%
Accumulate	10 to 20%
Reduce	0 to 10%
Sell	< 0%

Rating and Target Price History



Month	Rating	TP (Rs.)	Price (Rs.)
Nov-19	Buy	58	46
Feb-20	Buy	62	43
May-20	Buy	45	31
Jun-20	Buy	45	37
Aug-20	Buy	85	54
Aug-20	Buy	85	65

^{*}Price as on recommendation date

DART Team

Purvag Shah	Managing Director	purvag@dolatcapital.com	+9122 4096 9747		
Amit Khurana, CFA	Head of Equities	amit@dolatcapital.com	+9122 4096 9745		
CONTACT DETAILS					
Equity Sales	Designation	E-mail	Direct Lines		
Dinesh Bajaj	VP - Equity Sales	dineshb@dolatcapital.com	+9122 4096 9709		
Kapil Yadav	VP - Equity Sales	kapil@dolatcapital.com	+9122 4096 9735		
Yomika Agarwal	VP - Equity Sales	yomika@dolatcapital.com	+9122 4096 9772		
Jubbin Shah	VP - Derivatives Sales	jubbins@dolatcapital.com	+9122 4096 9779		
Ashwani Kandoi	AVP - Equity Sales	ashwanik@dolatcapital.com	+9122 4096 9725		
Lekha Nahar	AVP - Equity Sales	lekhan@dolatcapital.com	+9122 4096 9740		
Equity Trading	Designation	E-mail			
P. Sridhar	SVP and Head of Sales Trading	sridhar@dolatcapital.com	+9122 4096 9728		
Chandrakant Ware	VP - Sales Trading	chandrakant@dolatcapital.com	+9122 4096 9707		
Shirish Thakkar	VP - Head Domestic Derivatives Sales Trading	shirisht@dolatcapital.com	+9122 4096 9702		
Kartik Mehta	Asia Head Derivatives	kartikm@dolatcapital.com	+9122 4096 9715		
Dinesh Mehta	Co- Head Asia Derivatives	dinesh.mehta@dolatcapital.com	+9122 4096 9765		
Bhavin Mehta	VP - Derivatives Strategist	bhavinm@dolatcapital.com	+9122 4096 9705		



Analyst(s) Certification

The research analyst(s), with respect to each issuer and its securities covered by them in this research report, certify that: All of the views expressed in this research report accurately reflect his or her or their personal views about all of the issuers and their securities; and No part of his or her or their compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in this research report.

I. Analyst(s) and Associate (S) holding in the Stock(s): (Nil)

II. Disclaimer:

This research report has been prepared by Dolat Capital Market Private Limited. to provide information about the company(ies) and sector(s), if any, covered in the report and may be distributed by it and/or its affiliated company(ies) solely for the purpose of information of the select recipient of this report. This report and/or any part thereof, may not be duplicated in any form and/or reproduced or redistributed without the prior written consent of Dolat Capital Market Private Limited. This report has been prepared independent of the companies covered herein. Dolat Capital Market Private Limited. and its affiliated companies are part of a multi-service, integrated investment banking, brokerage and financing group. Dolat Capital Market Private Limited. and/or its affiliated company(ies) might have provided or may provide services in respect of managing offerings of securities, corporate finance, investment banking, mergers & acquisitions, financing or any other advisory services to the company(ies) covered herein. Dolat Capital Market Private Limited. and/or its affiliated company(ies) might have received or may receive compensation from the company(ies) mentioned in this report for rendering any of the above services. Research analysts and sales persons of Dolat Capital Market Private Limited. may provide important inputs to its affiliated company(ies) associated with it. While reasonable care has been taken in the preparation of this report, it does not purport to be a complete description of the securities, markets or developments referred to herein, and Dolat Capital Market Private Limited. does not warrant its accuracy or completeness. Dolat Capital Market Private Limited. may not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. This report is provided for information only and is not an investment advice and must not alone be taken as the basis for an investment decision. The investment discussed or views expressed herein may not be suitable for all investors. The user assumes the entire risk of any use made of this information. The information contained herein may be changed without notice and Dolat Capital Market Private Limited. reserves the right to make modifications and alterations to this statement as they may deem fit from time to time. Dolat Capital Market Private Limited. and its affiliated company(ies), their directors and employees may; (a) from time to time, have a long or short position in, and buy or sell the securities of the company(ies) mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions. This report is neither an offer nor solicitation of an offer to buy and/or sell any securities mentioned herein and/or not an official confirmation of any transaction. This report is not directed or intended for distribution to, or use by any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject Dolat Capital Market Private Limited. and/or its affiliated company(ies) to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to a certain category of investors. Persons in whose possession this report may come, are required to inform themselves of and to observe such restrictions.

For U.S. Entity/ persons only: This research report is a product of Dolat Capital Market Private Limited., which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution by Dolat Capital Market Private Limited. only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person or entity.

In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors, Dolat Capital Market Private Limited. has entered into an agreement with a U.S. registered broker-dealer Ltd Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer/Entity as informed by Dolat Capital Market Private Limited. from time to time.



Dolat Capital Market Private Limited.

Corporate Identity Number: U65990DD1993PTC009797

Member: BSE Limited and National Stock Exchange of India Limited.

SEBI Registration No: BSE - INB010710052 & INF010710052, NSE - INB230710031& INF230710031, Research: INH000000685

Registered office: Office No. 141, Centre Point, Somnath, Daman – 396 210, Daman & Diu

Board: +9122 40969700 | Fax: +9122 22651278 | Email: research@dolatcapital.com | www.dolatresearch.com